Yesterday, Merck (NYSE:MRK) licensed the rights to an over-the-counter (OTC) version of its cholesterol-lowering drug MEVACOR to GlaxoSmithKline (NYSE:GSK), but the deal is far from done. Merck has ...

Sept. 28, 2005 ( updated Oct. 6, 2005) -- The U.S. Food and Drug Administration (FDA) approved safety labeling revisions in June to advise that doxercalciferol dose reductions are recommended in ...

Merck's latest attempt to sell its oldest cholesterol-lowering drug, Mevacor, over the counter without a prescription is once again being questioned at the Food and Drug Administration. In preparation ...

An FDA advisory panel has rejected Merck’s bid to sell the cholesterol-lowering drug Mevacor without a prescription. The panel voted 10-2 against recommending OTC sales of the drug. The rejection ...

WASHINGTON — Government advisers on Thursday rejected Merck & Co.’s bid for over-the-counter sales of Mevacor, the granddaddy of the famed cholesterol-lowering drugs. Too many of the wrong people ...

An FDA panel was set to decide on Friday whether they will recommend approval for Merck’s plan to sell a cholesterol-lowering medicine on drugstore shelves without a prescription, Reuters reported.

U.S. government advisers rejected Merck & Co.'s latest bid for over-the-counter sales of Mevacor, the granddaddy of the famed cholesterol-lowering drugs. They said it is too complicated for consumers ...

As part of their new joint venture, Johnson & Johnson and Merck want to take their cholesterol-lowering drug Mevacor (lovastatin) from prescription to over-the-counter status, according to company ...

As expected, regulators in the USA have rejected Merck & Co’s bid to get the green light for an over-the-counter version of its cholesterol-lowerer Mevacor. As expected, regulators in the USA have ...

In 2009, pharmacists filled over 200 million prescriptions for statins, the drug that’s thought to prevent heart attacks and strokes. And, manufacturers of the drug, more commonly known as Zocor, ...

Merck & Co. on Friday said the Food and Drug Administration rejected its application to market an over-the-counter cholesterol drug. Subscribe to read this story ad-free Get unlimited access to ...